Pharmaceutical

Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO

Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as chief executive officer from 1 April 2025.

Feb 1, 2025 - 06:00
Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO
Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as chief executive officer from 1 April 2025.
Read the original article

Tags:

Previous Article

NHS England to offer Casgevy for sickle cell disease patients

Next Article

FDA approves Vertex’s acute pain treatment Journavx

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Medicare Advantage plans for dual-eligible enrollees set to get Senate scrutiny

STAT+: Medicare Advantage plans for dual-eligible enrol...

Sep 26, 2023

STAT+: FDA approves first treatment for skin condition that causes persistent wounds, a redosable gene therapy

STAT+: FDA approves first treatment for skin condition ...

May 19, 2023

ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific

ESMO 2024: BMS cuts ties as Immatics regains full right...

Sep 18, 2024